Paraguay vs Tajikistan: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Paraguay
- Tajikistan
How they compare
Tajikistan currently reports 827.83 deaths against 748.25 deaths in Paraguay, a difference of 79.58 deaths.
That makes Tajikistan's figure about 1.1 times Paraguay's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Tajikistan ahead.
Paraguay ranks 82nd and Tajikistan ranks 79th of 157 countries.
Across the 4 decades both report, Paraguay averaged higher in 2 and Tajikistan in 1.
Head to head by decade
| Decade | Paraguay | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 104.86 deaths | 10.42 deaths | 94.43 deaths | Paraguay |
| 2010s | 475.81 deaths | 340.73 deaths | 135.09 deaths | Paraguay |
| 2020s | 692.4 deaths | 755.08 deaths | 62.67 deaths | Tajikistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Paraguay or Tajikistan?
- Tajikistan, at 827.83 deaths against 748.25 deaths in Paraguay as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Paraguay and Tajikistan?
- 79.58 deaths, with Tajikistan ahead.
- How many years of comparable data are there for Paraguay and Tajikistan?
- 35 years are reported by both, from 1990 to 2024.
- How do Paraguay and Tajikistan rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Paraguay ranks 82nd and Tajikistan ranks 79th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.